BioSpace News Archive

Forecast to 2030,’ thoroughly examines the Brain Reading Robots industry to provide essential data & information for the targeted readers.

BioHarvest Sciences CEO Ilan Sobel will host the event, which will include coverage of Q2 sales results and a detailed progress update on the 2022 Growth Priorities, with specific focus on the VINIA scale-up progress in the USA and on the Company’s Cannabis market entry strategy into North America.

Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), announced today the completion of the phase 3 clinical trial investigating emixustat hydrochloride (“emixustat”) in patients with macular atrophy secondary to Stargardt disease.

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria.

4D pharma plc, a pharmaceutical company leading the development of Live Biotherapeutic products, a novel class of drug derived from the microbiome, provides an update to the announcement released earlier regarding the Company’s request for an immediate suspension of trading in the Company’s ordinary shares on AIM which took effect from 12.30 p.m.

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it will report second quarter 2022 financial results on Thursday, July 21, 2022, before the market opens.

Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 22,850 shares of the Company’s common stock at an exercise price per share of $24.98, which was the closing price on June 23, 2022, and restricted stock units to acquire a total of 11,425 shares of the Company’s common stock.

Sanyou Biopharmaceuticals, a biological high-tech enterprise focusing on R&D and services of innovative antibody drugs, and Dragon Sail Pharmaceutical, a CDMO and CMO enterprise dedicated to providing world-leading high-end biological drug manufacture services, announced a long-term strategic partnership taking effective.

argenx announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended European Commission approval of efgartigimod as an add-on to standard therapy for the treatment of adult patients with generalized myasthenia gravis who are anti-acetylcholine receptor antibody positive.

Celyad Oncology SA, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell therapies for cancer, announced that the Board of Directors has named Hilde Windels as Chairwoman of the Board of Directors, effective immediately.